肺癌纵隔分期:多学科协作的实践要点
纵隔淋巴结分期是肺癌高质量诊疗的标准,但临床常被忽视。本文由胸外科与呼吸科医生共同撰写,结合指南与文献,通过病例阐述纵隔分期的细微之处,强调多学科讨论在肺癌分期与治疗决策中的价值。
要点
- 纵隔淋巴结病理取样是肺癌分期的标准,遗漏可导致分期不准与治疗不当。
- 影像学明显或可疑的淋巴结均需病理证实,以指导治疗选择。
- 多学科讨论有助于优化肺癌纵隔分期与治疗决策。
核心结论
- 纵隔分期是肺癌高质量诊疗的标准,但常执行不足,需多学科协作推进。
研究设计与样本
- 本文为综述类文章,汇总相关指南与文献,并以病例场景展示纵隔分期方法。
主要发现
- 忽视病理淋巴结取样可导致分期过低或过高,进而造成治疗不当。
- 部分淋巴结病变影像学明显,部分不明显,两种情况均需病理证实。
临床怎么用
- 对已知或疑似肺癌患者应规范进行纵隔淋巴结病理分期。
- 影像学可见或可疑的纵隔淋巴结均需取样证实后再定治疗。
- 建议通过多学科讨论解决肺癌分期与治疗中的争议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mediastinal lymph node staging in the setting of known or suspected lung cancer is supported by multiple professional societies as standard for high-quality care, yet proper mediastinal staging often is lacking. Neglecting pathologic lymph node sampling can understage or overstage the patient and lead to inappropriate treatment. Although some cases of nodal disease are radiographically obvious, others are not as apparent, and both situations require pathologic proof to allow for appropriate treatment selection. This article discusses the nuances of mediastinal staging and emphasizes the usefulness of a multidisciplinary approach and dialog to address lung cancer staging and treatment. We summarize the relevant guidelines and literature and provide a case scenario to illustrate the approach to mediastinal staging from our viewpoints as a thoracic surgeon and pulmonologist.
引用
- Farjah F, Tanner NT. Mediastinal Staging for Lung Cancer. Chest. 2021. PMID: 34029567. doi:10.1016/j.chest.2021.05.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。